World Sleep Disorders Market, 2005-2010: A Market With High Growth Potential

PRLog (Press Release) – May 31, 2008 – The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first real competition for Ambien arrived on the market in the form of Estorra from Sepracor.

The purpose of this market report is to examine the factors that will influence the market and examine why It has a forecast for the market to grow to over $4.4 billion by 2010. The imminent pipeline products are examined in detail and their potential strengths and weaknesses compared. The futures of the older products are assessed. Non-product related factors are considered as the insomnia treatment market has attracted considerable negativity associated with poor side effects and in particular dependency.

The potential for market growth is enormous with only 10% of the estimated potential patient population of 150 million using prescribed pharmaceutical products for insomnia. Although insomnia is by far the most common sleep disorder, this report also considers the markets for:

Narcolepsy
Restless Leg Syndrome (RLS)
Obstructive Sleep Apnea (OSA).

Sanofi-Aventis is the leading company in the sleep disorder market, but over 25 companies are mentioned in this report. The report assesses which companies and products will be key companies by 2010.

Why you should buy this report :

It is a market that will more than double in size by 2010.
It is a market that will change from one dominant product to one with at least 5 key products.
Characteristics of an ideal sleep disorder treatment are compared with the current and pipeline products.
Ambien is key product for Sanofi-Aventis and is at a pivotal point in its life cycle. How this will affect the future sales levels for Sanofi-Aventis is assessed.
Sanofi-Aventis and Sepracor have significantly increased their level of DTC advertising. The importance of this and other non-product related factors are considered.

For anyone with or considering involvement with the sleep disorder market this report is the most recently published report to examine and consider all of the salient factors.

Companies Mentioned in This Report :

Alliance Pharma, Arena Pharmaceutical, Astellas, Celgene, Cephalon, Eli Lilly, Fujisawa Pharmaceutical
GSK, King Pharmaceuticals, Lundbeck, Merck, Merck KgaA, Neurocrine Bioscience, Neurogen, Novartis
Organon, Orphan, Pfizer, Sanofi-Aventis, Sepracor, Shering AG, Shire, Somaxon, Takeda, Pharmaceutical, Teva, Wyeth/Elan, Yamanouchi

For more information, kindly visit :
http://www.bharatbook.com/detail.asp?id=44669
________________________________________________